Copper (from 5mg GHK-Cu Copper Tripeptide-1) 0.5 mg
The 30% AHA group peels (Glycolic, Lactic, Kojic, Mandelic) are safe for all skin tones and have a mild strength
The compound's ability to act on dopaminergic and serotonergic pathways extends its repair activity into the nervous system, reflecting the multi-layered mechanism behind how BPC-157 works
Skin Care Routine Goal : Reduce inflammation, repair the skin barrier, and avoid triggers
These stacks aim to explore synergies between complementary pathways
Proposed Escalation Strategy A theoretical cagrilintide and retatrutide combination protocol might follow this gradual escalation approach: Weeks 1-4: Foundation Phase Cagrilintide: 0.6 mg weekly Retatrutide: 2 mg weekly Focus: Establishing tolerance to both compounds Monitoring: Gastrointestinal effects, appetite changes Weeks 5-8: Escalation Phase Cagrilintide: 1.2 mg weekly Retatrutide: 4 mg weekly Focus: Increasing receptor activation Monitoring: Weight changes, metabolic markers Weeks 9-12: Optimization Phase Cagrilintide: 2.4 mg weekly Retatrutide: 8 mg weekly Focus: Approaching therapeutic targets Monitoring: Comprehensive metabolic assessment Weeks 13+: Maintenance Phase Cagrilintide: 3.0-4.5 mg weekly Retatrutide: 8-12 mg weekly Focus: Sustained metabolic effects Monitoring: Long-term safety and efficacy This graduated approach mirrors the successful strategies used in cagrilintide 10mg research protocols, where slow escalation minimizes side effects while building therapeutic benefit
